<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9183">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02987387</url>
  </required_header>
  <id_info>
    <org_study_id>2015-10</org_study_id>
    <nct_id>NCT02987387</nct_id>
  </id_info>
  <brief_title>COMPASSION XT PAS - Post-approval Study of the SAPIEN XT THV in Patients With Pulmonary Valve Dysfunction</brief_title>
  <official_title>New Enrollment SAPIEN XT Post-Approval Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Edwards Lifesciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Edwards Lifesciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will confirm the safety and effectiveness of the Edwards Lifesciences SAPIEN XT
      Transcatheter Heart Valve (THV) System in patients with a dysfunctional right ventricular
      outflow tract (RVOT) conduit with a clinical indication for intervention in a post-market
      setting.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a prospective, non-randomized, multi-center clinical study to assess the safety
      and effectiveness of pulmonic implantation of the SAPIEN THV in patients with dysfunctional
      RVOT conduits requiring treatment for moderate or severe pulmonary regurgitation (PR) by
      transthoracic echocardiography (TTE) and/or RVOT conduit obstruction with a mean gradient of
      â‰¥ 35 mmHg by TTE.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2017</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from device- or procedure-related death or reintervention</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Decrease in pulmonary regurgitation to mild or less for regurgitant lesions</measure>
    <time_frame>1 year</time_frame>
    <description>Assessed via transthoracic echocardiogram (TTE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease in RVOT mean gradient to less than 30 mmHg for stenotic lesions</measure>
    <time_frame>1 year</time_frame>
    <description>Assessed via TTE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device Success</measure>
    <time_frame>48 Hours Prior to Discharge</time_frame>
    <description>Device Success is a composite of:
Deployment of the valve to the target area, and
Removal of the delivery catheter out of the body, and
Improvement in pulmonary regurgitation to mild or less per the earliest evaluable TTE.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">191</enrollment>
  <condition>Pulmonary Valve Insufficiency</condition>
  <condition>Pulmonary Valve Stenosis</condition>
  <condition>Heart Defects, Congenital</condition>
  <condition>Congenital Abnormalities</condition>
  <condition>Cardiovascular Diseases</condition>
  <condition>Heart Diseases</condition>
  <arm_group>
    <arm_group_label>TPVI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transcatheter Pulmonary Valve Implantation with the SAPIEN XT THV</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SAPIEN XT THV</intervention_name>
    <description>SAPIEN XT THV will be implanted in the pulmonic position.</description>
    <arm_group_label>TPVI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient has a dysfunctional, non-compliant RVOT conduit.

          2. The patient/patient's legally authorized representative has been informed of the
             nature of the study, agrees to its provisions and has provided written informed
             consent.

        Exclusion Criteria:

          1. Inability to tolerate an anticoagulation/antiplatelet regimen

          2. Active bacterial endocarditis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John F. Rhodes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nicklaus Children's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sara Scrivano</last_name>
    <email>Sara_Scrivano@Edwards.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tenley Koepnick</last_name>
    <phone>949-250-6504</phone>
    <email>Tenley_Koepnick@Edwards.com</email>
  </overall_contact_backup>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 27, 2017</lastchanged_date>
  <firstreceived_date>October 19, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tetralogy of Fallot</keyword>
  <keyword>Aortic Valve Defect/Disease Resulting in Ross Procedure</keyword>
  <keyword>Transcatheter pulmonary valve implantation</keyword>
  <keyword>Transcatheter pulmonary valve replacement</keyword>
  <keyword>Pulmonary Atresia</keyword>
  <keyword>Pulmonary Stenosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Congenital Abnormalities</mesh_term>
    <mesh_term>Heart Defects, Congenital</mesh_term>
    <mesh_term>Pulmonary Valve Insufficiency</mesh_term>
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Pulmonary Valve Stenosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
